Navigation Links
Hypogonadism in Medical Technology

FDA Accepts Complete Response Submission to New Drug Application for NEBIDO(R)

... in Europe and other territories. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ... impair quality of life. Common effects of hypogonadism include decreased sexual desire, erectile ...

Indevus Announces Submission of New Drug Application

... reported were comparable to other injectable hypogonadism treatments reported in the literature. There were ... Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical ...

Novel Testosterone Gel Significantly Improves Insulin Sensitivity and Sexual Function in Hypogonadal Men With Type 2 Diabetes and Metabolic Syndrome

... 40-69 years, it is estimated that there are about 481,000 new cases of hypogonadism per year. Overall, approximately 2.4 million U.S. men suffer from the condition.(1) hypogonadism results from a deficiency in testosterone secretion that may occur ...

Indevus Presents Successful Phase III NEBIDO(R) Data at American Urological Association

... previously announced, are based on a Phase III study in which men with hypogonadism and low serum testosterone levels prior to entering the study were treated ... Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced ...

QuatRx Completes Enrollment of Ophena(TM)(Ospemifene Tablets) Final Pivotal Phase 3 Study in Women with Postmenopausal Vaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 as an oral treatment for the symptoms of secondary hypogonadism and other conditions in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. ...

QuatRx Pharmaceuticals Announces Additional Data From Phase 3 Study for Ophena(TM) (Ospemifene Tablets) Showing Improvements in Clinical Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

QuatRx Initiates Second Phase 3 Study of Ophena(TM) (Ospemifene Tablets) in Women With Postmenopausal Vaginal Syndrome

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 as a potential treatment for dyslipidemia. Becocalcidiol, a novel ...

Quatrx Pharmaceuticals Presents Results From Ophena(TM) (Ospemifene Tablets) Phase 3 Study Related to Treatment of Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

Auxilium Pharmaceuticals, Inc. Announces XIAFLEX(TM) Meets Primary Endpoint With Statistical Significance (p<0.001) in CORD I Pivotal Phase III Study for Dupuytren's Contracture

... endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial ...

QuatRx Pharmaceuticals Announces Presentation of Further Data from Ophena(TM) (Ospemifene) Phase 3 Study for Treatment of Symptoms of Vulvovaginal Atrophy

... program. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. Sobetirome, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for dyslipidemia. Asord(TM) ...

Indevus Reports Additional Positive Phase III Trial Data for NEBIDO(R)

... replacement therapies. Indevus acquired U.S. rights to NEBIDO from Bayer Schering Pharma AG, Germany in July 2005. About Hypogonadism Male hypogonadism is an increasingly recognized medical condition characterized by a reduced or absent secretion of testosterone from the testes. Reduced testosterone ...

QuatRx Pharmaceuticals Announces Positive Phase 3 Results for Study of Ophena(TM) (ospemifene) to Treat Postmenopausal Vaginal Syndrome

... programs. Fispemifene is a new selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. ...

QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome

... programs. Fispemifene is a new, selective estrogen receptor antagonist that is in Phase 2 studies as an oral treatment for the symptoms of secondary hypogonadism in men. QRX-431, a novel, selective thyroid receptor beta agonist, is in Phase 1 studies as a potential treatment for lipid disorders and obesity. ...

Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)

... endocrinologists, orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. XIAFLEX(TM) (clostridial ...

Repros' Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism

... or hypothalamic dysfunction, when diagnosing hypogonadism in men." Although the syndrome of secondary hypogonadism is characterized by the objective measurements of ... potential to change the way in which secondary hypogonadism is treated in the future." Repros anticipates ...

Indevus Reports Positive Data From Phase III NEBIDO Trial

... under development for the treatment of male hypogonadism which the Company licensed from Bayer Schering ... Schering Pharma AG, Germany in July 2005. About hypogonadism Male hypogonadism is an increasingly recognized medical condition ...

New Poll Shows Men, Women Incorrectly Blame Symptoms of Low Testosterone on Normal Aging

... of their current relationship. About hypogonadism (Low Testosterone) Physical signs of hypogonadism can include incomplete sexual development, body ... sperm production. Symptoms associated with hypogonadism can include reduced sexual desire, depression, ...

Auxilium Announces New Data That Show Total Testosterone Blood Levels Increase Significantly Following Switch from AndroGel(R) to Testim(R)

... an initial inadequate response. About hypogonadism Low testosterone ("Low T"), or hypogonadism, is ... testosterone production. Physical signs of hypogonadism can include incomplete sexual development, body ... a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and ...

Columbia Laboratories Reports Preliminary Findings from the Ongoing Data Analysis of the Phase III Clinical Study of PROCHIEVE 8% (progesterone gel) to Prevent Preterm Birth

... (progesterone gel) for the treatment of secondary amenorrhea. The Company also markets STRIANT(R) (testosterone buccal system) for the treatment of hypogonadism in men. For more information, please visit www.columbialabs.com. Safe Harbor Statement Under the Private Securities Litigation Reform Act of 1995: ...

Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference

... orthopedists and select primary care physicians. Auxilium markets Testim(R) 1%, a topical testosterone gel, for the treatment of hypogonadism through its approximately 190-person sales and marketing team. Auxilium has four projects in clinical development. AA4500, an injectable collagenase ...
Other Contents
(Date:12/19/2014)... Calif. , Dec. 18, 2014  23andMe, Inc., ... of a study that pinpoints fine-scale differences in genetic ... States . Since immigrants first arrived ... United States has served as a meeting ... how American history and the ongoing mixing of peoples ...
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... YORK , Dec. 15, 2014  HITLAB ... Good Clinical Practices (GCP) audit to confirm its ... (FDA) regulations. This accomplishment enables HITLAB to conduct ... utilizing the highest principles for patient safety and ... improve global healthcare access, quality, and delivery with ...
Breaking Biology News(10 mins):23andMe Study Sketches Genetic Portrait of the United States 223andMe Study Sketches Genetic Portrait of the United States 323andMe Study Sketches Genetic Portrait of the United States 4Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
(Date:12/22/2014)... December 22, 2014 The Bob ... ever, having invested more than $5 million in ... veterans and their families. , This includes $1.3 ... dozen nonprofits, helping with: veteran entrepreneurship; community impact; ... life-coaches for severely injured veterans. , “The needs ...
(Date:12/22/2014)... 2014 Give a loved one the ... of health and vitality. , For a limited time, ... anti-aging formulas in special Holiday Wellness gift packages at ... , Each bottle contains cutting-edge, proven nutritional support for ... as well as we age. , Joint ...
(Date:12/22/2014)... 22, 2014 Xarelto Lawsuit News ... of judges has granted a request to centralize pending ... District Court, Eastern District of Louisiana. The U.S. Judicial ... December 12 to transfer over 50 Xarelto cases–21 lawsuits ... the Louisiana court for consolidation under U.S. District Judge ...
(Date:12/22/2014)... St. Petersburg, FL (PRWEB) December 22, 2014 ... needed. Sublime Beauty® has a fast and easy solution that ... online gift cards can be purchased from from $25 up ... ®. "We offer 100% customer satisfaction and a wide array ... cards have no fees and no expiration dates. , ...
(Date:12/22/2014)... December 22, 2014 The ... professional development programs this month. Faculty have been ... on nurse educators fast-tracked for administrative leadership roles ... Development Program for Simulation Educators, featuring a curriculum ... of nursing education. , Twenty nurse educators ...
Breaking Medicine News(10 mins):Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 2Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 3Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 4Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 5Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 6Health News:Bob Woodruff Foundation Poised to Reach More Vets Thanks to Banner Year 7Health News:You Still Have Time to Give the Gift of Health and Vitality to a Mature Loved One 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 2Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 3Health News:Panel Orders Xarelto Lawsuits Consolidated Into Multi-District Litigation Reports Alonso Krangle LLP 4Health News:NLN Leadership Institute Announces 2015 Cohorts 2Health News:NLN Leadership Institute Announces 2015 Cohorts 3
Other TagsOther Tags